Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies for hematologic diseases, with a lead focus on the small molecule CXCR4 antagonist burixafor (GPC-100). The Exicure news feed highlights how the company advances this program across multiple indications and how its financial and corporate decisions affect the XCUR stock story.
Readers can follow updates on Exicure’s clinical trials, including an open-label, multicenter Phase 2 study of burixafor in combination with propranolol and G-CSF in patients with multiple myeloma undergoing autologous hematopoietic cell or stem cell transplantation. Company announcements describe topline and interim results, rates of successful CD34+ cell mobilization, engraftment outcomes for participants who proceed to transplant, and safety observations for the burixafor-based regimen.
News items also cover pipeline expansion plans, where Exicure discusses potential use of burixafor in sickle cell disease, rare diseases requiring autologous transplant, cell and gene therapy settings, and as a potential chemosensitizing agent in acute myeloid leukemia (AML). These releases outline how mobilizing hematopoietic or malignant cells from the bone marrow niche into peripheral blood could support transplant procedures or enhance chemotherapy effectiveness.
In addition, the XCUR news stream includes financial results and going concern disclosures, detailing quarterly cash balances, research and development and general and administrative expenses, and management’s assessment that additional financing is needed to fund operations and strategic alternatives. Corporate governance and listing-related developments, such as Nasdaq compliance notices, annual meeting information, and board composition changes, are also reported.
Investors and followers of Exicure can use this page to monitor clinical data presentations, strategic updates related to the acquisition of GPCR Therapeutics USA Inc., and regulatory or capital markets filings that shape the company’s hematology-focused trajectory. Bookmark this feed to review new press releases and regulatory-linked news as they are published.
Exicure, Inc. (NASDAQ: XCUR) reported Q1 2021 results, highlighting significant advancements in clinical programs and board expansion. The FDA granted Fast Track and Orphan Drug designations for cavrotolimod (AST-008) aimed at treating advanced Merkel cell carcinoma and squamous cell carcinoma. The company is on track to submit an IND for XCUR-FXN for Friedreich's Ataxia by year-end 2021. Financially, the company reported a net loss of $12.5 million, up from a $1.2 million net income year-over-year, while cash reserves decreased to $67.4 million.
Exicure, Inc. (NASDAQ: XCUR) reported that Northwestern University researchers successfully utilized its gold-nanoparticle SNA technology in a first-in-human trial targeting glioblastoma (GBM). The phase 0 trial showed that intravenously administered siRNA-based SNAs can safely cross the blood-brain barrier and target the oncogene Bcl2L12. These findings, published in Science Translational Medicine, mark a significant milestone for Exicure’s technology in treating GBM. The company also plans to file an IND for Friedreich's ataxia by the end of 2021.
Exicure, Inc. (NASDAQ:XCUR) reported impressive financial results for 2020, achieving $16.6 million in revenue, up from $1.3 million in 2019, primarily due to a collaboration with AbbVie. The net loss reduced to $24.7 million from $26.3 million year-over-year. Key advancements included the initiation of IND-enabling studies for XCUR-FXN targeting Friedreich’s ataxia and multiple FDA designations for cavrotolimod (AST-008), enhancing its oncology pipeline. Despite COVID-19 related delays, Exicure expects sufficient cash runway for the next 12 months to support ongoing trials.
Exicure, Inc. (NASDAQ: XCUR) has announced the addition of Elizabeth Garofalo, M.D. and Andrew Sassine to its Board of Directors during a pivotal time for the company. The appointments are expected to enhance Exicure's development of its investigational drugs, cavrotolimod and XCUR-FXN. Garofalo brings over 25 years of clinical development experience, while Sassine contributes extensive financial expertise. Additionally, David Walt, Ph.D. will not seek re-election at the upcoming Annual Meeting. Exicure focuses on innovative therapies utilizing its proprietary Spherical Nucleic Acid technology.
Exicure, Inc. (NASDAQ: XCUR) announced that the FDA has granted Orphan Drug Designation for its candidate cavrotolimod (AST-008) targeting Merkel cell carcinoma (MCC). This designation is a significant step towards addressing unmet medical needs for MCC patients. Exicure previously received Fast Track designations for cavrotolimod for MCC and cutaneous squamous cell carcinoma (CSCC). Cavrotolimod is currently in Phase 1b/2 clinical trials, showing promising anti-tumor activity with no serious adverse events reported thus far.
Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available for registered attendees to view on-demand starting March 9, 2021, at 7:00 AM EST, and it will be archived for 90 days. Exicure is a biotechnology firm focusing on gene regulatory therapies using its proprietary Spherical Nucleic Acid (SNA) technology, currently in preclinical development for Friedreich’s ataxia and advancing in clinical trials for solid tumors.
Exicure, Inc. (Nasdaq: XCUR) has announced its participation in 1x1 meetings with institutional investors at the 10th Annual SV Leerink Global Healthcare Conference from February 24 to 26, 2021. The company focuses on gene regulatory and immunotherapeutic drug development using its proprietary Spherical Nucleic Acid (SNA™) technology. Exicure is currently advancing its drug candidate XCUR-FXN for Friedreich’s ataxia and conducting a Phase 1b/2 trial for AST-008 in advanced solid tumors. The company is headquartered in Chicago, IL, with an office in Cambridge, MA.
Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available for on-demand viewing for registered attendees beginning February 15, 2021. Attendees can schedule 1x1 meetings with Exicure during the conference. With a focus on gene regulatory and immunotherapeutic drugs, Exicure is developing therapeutics targeting neurological and inflammatory diseases utilizing its proprietary Spherical Nucleic Acid (SNA) technology.
Exicure, Inc. (NASDAQ: XCUR) has received Fast Track designations from the FDA for cavrotolimod (AST-008) targeting advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma, both refractory to prior therapies. Cavrotolimod enhances immune responses and is currently in a Phase 1b/2 trial, showing a 21% overall response rate in evaluable patients, including durable responses exceeding six months. No serious adverse events were reported, and significant immune cell activation was observed. This designation highlights the urgent need for novel therapies in these cancer types.
Exicure, Inc. (NASDAQ: XCUR) has appointed James Sulat to its Board of Directors, bringing extensive biopharmaceutical experience. Sulat has held leadership roles at various firms and currently serves on the boards of Valneva SE and Arch Therapeutics. His background in business development and finance is expected to support Exicure's growth. Additionally, Jay Venkatesan has resigned from the Board, effective December 29, 2020. The company focuses on gene regulatory therapies targeting cancer and genetic disorders using its proprietary SNA™ technology, with its lead program in a Phase 1b/2 trial.